Uganda has launched a trial vaccination program to combat the Sudan strain of the Ebola virus after an increase in confirmed cases.
The World Health Organization (WHO) confirmed that the trial began following the virus’s re-emergence in Kampala, where a nurse died from the infection on January 29.
Health ministry spokesperson Emmanuel Ainebyoona reported that the total cases have increased to three, with two additional infections identified in the deceased nurse’s family.
WHO Africa Director Matshidiso Moeti announced that Uganda has started testing a vaccine specifically targeting the Sudan strain of Ebola.
Unlike the existing Zaire strain vaccine, used in the Democratic Republic of Congo, no approved vaccine exists for the Sudan strain.
“This is a major milestone in public health emergency response and global health security,” Moeti said. “If successful, the vaccine will enhance protection against future outbreaks.”
The International AIDS Vaccine Initiative (IAVI) developed the vaccine, supplying 2,460 doses to Uganda. Bruce Kirenga, head of Makerere Lung Institute, confirmed that the health ministry will prioritize vaccinating individuals who have been in contact with confirmed Ebola patients.
Ebola Risks and Transmission
Ebola is a high-fatality disease causing hemorrhage, headaches, and muscle pain. The virus spreads through direct contact with infected bodily fluids and tissues, making early intervention critical.
With the trial vaccine rollout underway, health authorities aim to contain the outbreak and develop long-term preventive strategies.
